Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qirong Fuzheng Mixture Phase III in HIV/AIDS patients on stable HAART
ChiCTR2400082394Phase 3Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Mar 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of qirong fuzheng mixture in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Change in CD4+ cell count from baseline at 24 weeks. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
qirong fuzheng mixture
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2400082394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082394.